TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Relative bioavailability (Frel) according to the model independent approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival events
Endpoint domain: Mortality/survival
Primary endpoint: Insulin Sensitivity Utilizing the Euglycemic Hyperinsulinemic Clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin Sensitivity Utilizing Endothelial Function as Assessed by Pulse Volume Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Height and Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of experimental sites becoming closed pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversion of Minimal Hepatic Encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte Concentration (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC [0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak subjective fear upon exposure to heights
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent goal enteral calories received
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Delta Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Seroprotection Against Hepatitis B and Haemophilus Influenzae Type b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Treatment Discontinuations Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Scores on Bayley scales of infant and toddler development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: S-25OHD concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in nonmenstrual pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaccine-related unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: vaccine-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: aneurysms related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRS score on day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline NIHSS score on day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in incidence of cardiac toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Numeric Rating Scale (NRS) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% Disease Improvement by the End of Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Composite Asthma Severity Index (CASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the device in eradicating, decreasing or downgrading of the lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of adverse effects per patient treated with LOSEC
Endpoint domain: Adverse events/effects
Primary endpoint: levels of iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: levels of ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: chemistry panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of immediate post surgery complications
Endpoint domain: Adverse events/effects
Primary endpoint: overall short term tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of bone by CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite measure of viral delivery and spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Evaluation of bacterial microbiota on psoriasis lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Evaluation of bacterial microbiota on surrounding healthy skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Graft survival at month 12
Endpoint domain: Mortality/survival
Primary endpoint: Change in Glycemic Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Diabetes Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Psychosocial Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Circulating Inflammatory Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Engagement (shared engagement in a play routine) at 2 weeks
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Joint Engagement (shared engagement in a play routine) at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Joint Engagement (shared engagement in a play routine) at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Plasma AUCinf of PF 00299804
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of PF 00299804
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of PF 00299804
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to statin use decision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spatial span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-Reported Home Smoking Restrictions
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in ARAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH-CPSI pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to acute pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of acute pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in urge incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Operative Urinary Retention (POUR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of successful implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in contrast sensitivity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in contrast threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton-Depression Rating Scale (HDRS-24 Items)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: In-hospital outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects exhibiting increases in papules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of subjects exhibiting increases in erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of subjects exhibiting increases in dryness, telangiectasia and tactile surface roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of subjects exhibiting increases in any subjective irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: operative and postoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ambulance Response Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum tolerated dose of sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Pain Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Questionnaire applicability rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Amount of Skin Fauna
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in aortic pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lower incisors stability after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: lower incisors stability after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Tracheal length (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LMB diameter (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMB diameter (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal LMB curvature (TLMBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal RMB curvature (TRMBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Infection or Disruption
Endpoint domain: Adverse events/effects
Primary endpoint: prevalence of fatty liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in blood lipid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of enrolled subjects
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical improvement measured by SASSAD index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Parental understanding of informed consent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Burden of Care
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: PD-L1 in bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CTLA-4 in bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mucin-domain containing-3 (TIM-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PD-1 in bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum VEGF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma total bile acids in fasting state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Subjective Symptoms Self-report of Overall Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in antibody titre levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease Activity Score (DAS) 28 Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: European League Against Rheumatism (EULAR) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css max (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCττ (ng/mL*h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nocturnal hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Lesion Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported coping and problem solving
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-reported self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported hope
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to achieve bilateral sensory block at T10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression-free Survival Following Autologous Stem Cell Transplant (ASCT)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of condom protected acts of vaginal and anal intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The number of incidents of unclean syringes or needles in the past 90 days
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of injection acts in which unclean needles or syringes were used in the past 90 days
Endpoint domain: Adverse events/effects
Primary endpoint: The number of acts of unprotected vaginal and anal intercourse during the 90 days prior to the assessment period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequacy of medical history collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of MOUD injections received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of opioid relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of KRAS mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 21-item Hamilton Depression Rating Scale Score (HAM-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Compensatory and gustatory sweating
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Mastalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Mastalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of circulating tumor cells (CTCs) per milliliter of whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Etiologies of Fever Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Freedom from documented episode of AT or AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Right Ventricular Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wong Baker Scale (WBS) for Procedural Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety (state anxiety intraprocedure)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients With Reliable Cortical and Sub-cortical Brain Signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post operative pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEG Relative Gamma Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Modified Total Sharp X-Ray Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neonatal Birth Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of serum markers of CNS injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Expression of pro and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of Lithium Carbonate treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Lithium Carbonate treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Tinnitus handicap inventory (THI) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to recovery to TOF ratio of 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cue-elicited craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Evoked Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Electroretinogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mutation rate of BRAF, KRAS, and EGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefits (stable disease or partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circadian Rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forgotten Joint Score-12 (FJS-12)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analog Scale for Pain (VAS-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of stroke recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Structural state of the renal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Preventable Harms (Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Sphere refraction measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cylinder refraction measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent Febrile or Symptomatic Urinary Tract Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in extent and degree of synovitis in the hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants Achieving Sustained Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurogenic Bladder Symptom Score (NBSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCI-QOL Difficulties
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SCI-QOL Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term safety of rituximab
Endpoint domain: Adverse events/effects
Primary endpoint: COVID-19 specific TCR sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients reaching clear or almost clear on Physician's Global Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FXR-dependent metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Best overall response rate (PR + CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody rise to varicella zoster virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of positive ctDNA postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of positive ctDNA preoperative converted to negative postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Depression Residual Symptom Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in echocardiographic indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in serological indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the ANB angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to End of Treatment in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline to End of Treatment in Clinical Alanine Aminotransferase Serum Chemistry Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to End of Treatment in Clinical Blood Urea Nitrogen Serum Chemistry Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: cough during extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in WOMAC Pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Medical Abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes